Evidence map›Paper›PMID 31941474›Full record

ArticleBMC ophthalmology2020

Ex vivo anti-microbial efficacy of various formaldehyde releasers against antibiotic resistant and antibiotic sensitive microorganisms involved in infectious keratitis.

Daeryl E Amponin, Joanna Przybek-Skrzypecka, Mariya Zyablitskaya, Anna Takaoka, Leejee H Suh, Takayuki Nagasaki, Stephen L Trokel, David C Paik

Open access · goldAbstract readComparative Study
In one paragraph

Article in BMC ophthalmology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.3field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Complicated Diagnosis and Treatment of Rare PainlessJournal of clinical medicine · 2025
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 3 countries.

Daeryl E AmponinDepartment of Ophthalmology, Edward S. Harkness Eye Institute, Columbia University College of Physicians and Surgeons, 635 West 165th Street, Research Annex Room 715, New York, NY, 10032, USA.
Joanna Przybek-SkrzypeckaDepartment of Experimental and Clinical Pharmacology, Medical University of Warsaw, Warsaw, Poland.
Mariya ZyablitskayaDepartment of Ophthalmology, Edward S. Harkness Eye Institute, Columbia University College of Physicians and Surgeons, 635 West 165th Street, Research Annex Room 715, New York, NY, 10032, USA.
Anna TakaokaDepartment of Ophthalmology, Edward S. Harkness Eye Institute, Columbia University College of Physicians and Surgeons, 635 West 165th Street, Research Annex Room 715, New York, NY, 10032, USA.
Leejee H SuhDepartment of Ophthalmology, Edward S. Harkness Eye Institute, Columbia University College of Physicians and Surgeons, 635 West 165th Street, Research Annex Room 715, New York, NY, 10032, USA.
Takayuki NagasakiDepartment of Ophthalmology, Edward S. Harkness Eye Institute, Columbia University College of Physicians and Surgeons, 635 West 165th Street, Research Annex Room 715, New York, NY, 10032, USA.
Stephen L TrokelDepartment of Ophthalmology, Edward S. Harkness Eye Institute, Columbia University College of Physicians and Surgeons, 635 West 165th Street, Research Annex Room 715, New York, NY, 10032, USA.
David C PaikDepartment of Ophthalmology, Edward S. Harkness Eye Institute, Columbia University College of Physicians and Surgeons, 635 West 165th Street, Research Annex Room 715, New York, NY, 10032, USA. dcp14@cumc.columbia.edu.ORCID http://orcid.org/0000-0001-9074-5396
Columbia College · CAColumbia University · USMedical University of Warsaw · PL

Funding

CTSA INFRASTRUCTURE FOR PEDIATRIC RESEARCHUL1RR024156 · NCRR · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI GINSBERG, HENRY N · 2006 to 2011
$53.0M
Instrumentation, Fabrication, and Design CoreP30EY019007 · NEI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Xin Zhang · 2010 to 2026
$12.9M
Therapeutic Corneal Cross-Linking Using Formaldehyde Releasing AgentsR01EY020495 · NEI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI PAIK, DAVID C · 2011 to 2019
$3.6M
Foundation for the National Institutes of Health NEI P30 EY019007Foundation for the National Institutes of Health NEI R01EY020495NCRR NIH HHS UL1 RR024156NEI NIH HHS P30 EY019007NEI NIH HHS R01 EY020495NIH HHS NCRR UL1RR024156
6 · The paper itself

Abstract

backgroundCorneal infections with antibiotic-resistant microorganisms are an increasingly difficult management challenge and chemically or photochemically cross-linking the cornea for therapy presents a unique approach to managing such infections since both direct microbial pathogens killing and matrix stabilization can occur simultaneously. The present study was undertaken in order to compare the anti-microbial efficacy, in vitro, of 5 candidate cross-linking solutions against 5 different microbial pathogens with relevance to infectious keratitis.

methodsIn vitro bactericidal efficacy studies were carried out using 5 different FARs [diazolidinyl urea (DAU), 1,3-bis(hydroxymethyl)-5,5-dimethylimidazolidine-2,4-dione (DMDM), sodium hydroxymethylglycinate (SMG), 2-(hydroxymethyl)-2-nitro-1,3-propanediol (NT = nitrotriol), 2-nitro-1-propanol (NP)] against 5 different microbial pathogens including two antibiotic-resistant species [methicillin-sensitive Staphylococcus aureus (MSSA), methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Enterococcus (VRE), Pseudomonas aeruginosa (PA), and Candida albicans (CA)]. Standard in vitro antimicrobial testing methods were used.

resultsThe results for MSSA were similar to those for MRSA. DAU, DMDM, and SMG all showed effectiveness with greater effects generally observed with longer incubation times and higher concentrations. Against MRSA, 40 mM SMG at 120 min showed a > 95% kill rate, p < 0.02. Against VRE, 40 mM DAU for 120 min showed a > 94% kill rate, p < 0.001. All FARs showed bactericidal effect against Pseudomonas aeruginosa, making PA the most susceptible of the strains tested. Candida showed relative resistance to these compounds, requiring high concentrations (100 mM) to achieve kill rates greater than 50%.

conclusionOur results show that each FAR compound has different effects against different cultures. Our antimicrobial armamentarium could potentially be broadened by DAU, DMDM, SMG and other FARs for antibiotic-resistant keratitis. Further testing in live animal models are indicated.

Indexed as

Anti-Bacterial AgentsAntifungal AgentsBacteriaCandida albicansCorneal UlcerDrug ResistanceDrug Resistance, BacterialEye Infections, BacterialEye Infections, FungalFormaldehydeMicrobial Sensitivity TestsNitro CompoundsPropanolsSarcosineTromethamineUrea2-(hydroxymethyl)-2-nitro-1,3-propanediol2-nitropropanolAnti-Bacterial AgentsAntifungal AgentsdiazolidinylureaFormaldehydemonomethylolglycineNitro CompoundsPropanolsSarcosineTromethamineUreaAntibiotic resistant microorganismsFormaldehyde releasers (FARs)Infectious keratitisMethicillin-resistant Staphylococcus aureus (MRSA)Sodium hydroxymethylglycinateTissue cross-linking

Identifiers

PMID31941474
PMCPMC6964009
OpenAlexW3013619989

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.